A meta-analysis showed that elevated ezrin expression is associated with worse prognosis in patients with different cancer types (e.g., digestive cancers, head and neck squamous cell carcinoma, gynecological cancers, osteosarcoma, hepatobiliary cancer, and non-small cell lung cancer) [36]. Here, EZR is linked to non-small cell lung carcinoma.